UTIs

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs
VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs
Pharmaceutical Business Review
VenatoRx
clinical trials
UTIs
complicated urinary tract infections
cefepime
VNRX-5133
Flag link:
Merck's combination antibiotic scores FDA approval for urinary tract and abdominal infections
Merck's combination antibiotic scores FDA approval for urinary tract and abdominal infections
Endpoints
Merck
FDA
UTIs
intra-abdominal infections
Recarbrio
Flag link:
Nearing phase 3, resTORbio posts new data on infection drug
Nearing phase 3, resTORbio posts new data on infection drug
Fierce Biotech
ResTORbio
RTB101
respiratory infections
UTIs
Flag link:
It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
Fierce Pharma
Achaogen
FDA
Zemdri
antibiotics
UTIs
Flag link:
Achaogen's stock rockets after positive UTI drug trial results
Achaogen's stock rockets after positive UTI drug trial results
Marketwatch
Achaogen
UTIs
clinical trials
plazomicin
Flag link: